Nomegestrol acetate

Research use only, not for human use.

Nomegestrol acetate is a widely used progestin-like drugwhich is characterized as a full agonist at the progesterone receptor.

Nomegestrol acetate is a widely used progestin-like drugwhich is characterized as a full agonist at the progesterone receptor.(In Vitro):Nomegestrol acetate (0.3, 1, 3, 10, 30, 100 μM; 24, 48, 72 h) shows anti-proliferative activity against RL95-2 cells in a dose-dependent manner.Nomegestrol acetate (4, 20, 100 μM; 6, 24, 48 h) upregulates protein levels of SUFU and Wnt7a in RL95-2 cells.(In Vivo):Nomegestrol acetate (50, 100, 200 mg/kg; p.o.; single daily for 28 days) inhibits growth of RL95-2 xenograft tumors in vivo.Nomegestrol acetate (100, 200 mg/kg; p.o.; single daily for 28 days) surpresses the expression of SUFU and Wnt7a in tumor tissues.Nomegestrol acetate (1, 2.5 mg/rat; p.o.; single daily for 4 days) inhibits ovulation in rats.

Nomegestrol acetate (0.3, 1, 3, 10, 30, 100 μM; 24, 48, 72 h) shows anti-proliferative activity against RL95-2 cells in a dose-dependent manner.Nomegestrol acetate (4, 20, 100 μM; 6, 24, 48 h) upregulates protein levels of SUFU and Wnt7a in RL95-2 cells. Cell Proliferation Assay Cell Line:RL95-2 cells Concentration:0.3, 1, 3, 10, 30, and 100 μM Incubation Time:24, 48, 72 h Result:Inhibited the growth of RL95-2 cells in a concentration-dependent manner, with IC50 values of 19.88, 21.62 and 52.80 μM for 48, 72 and 24 h.Western Blot Analysis Cell Line:RL95-2 cells Concentration:4, 20, 100 μM Incubation Time:6, 24, 48 h Result:Increased the protein levels of SUFU and Wnt7a (relative to GAPDH expression) in a concentration-dependent manner.

Nomegestrol acetate (50, 100, 200 mg/kg; p.o.; single daily for 28 days) inhibits growth of RL95-2 xenograft tumors in vivo.Nomegestrol acetate (100, 200 mg/kg; p.o.; single daily for 28 days) surpresses the expression of SUFU and Wnt7a in tumor tissues.Nomegestrol acetate (1, 2.5 mg/rat; p.o.; single daily for 4 days) inhibits ovulation in rats. Animal Model:Female athymic nude mice (BALB/c; 18-20 g; 6 to 7-week-old; xenograft nude mouse model).Dosage:50, 100, 200 mg/kg Administration:Oral gavage; single daily for 28 days Result:Reduced the growth of RL95-2 xenograft tumors in vivo.Upregulated the expression of SUFU and Wnt7a in a dose-dependent manner when at 100 and 200 mg/kg.Animal Model:Mature female Wistar rats (~200 g).Dosage:1, 2.5 mg/rat Administration:Oral administration; single daily for 4 daysResult:Showed only one animal ovulated after receiving 1 mg/kg per day, and no animals ovulated after receiving 2.5 mg/rat per day.

——

Nuclear Receptor/Transcription Factor

Progesterone Receptor

progesterone receptor

Metabolic Disease

Healthy Postmenopausal Females

58652-20-3

370.48

C23H30O4

>98% (HPLC)

DMSO:62.5 mg/mL (168.70 mM; Need ultrasonic)

[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H]

——

(-20℃)

With Ice Pack

≥ 2 years